Melphalan, thalidomide and dexamethasone (DrugBank: Thalidomide, Melphalan, Dexamethasone)
25 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
13 | Multiple sclerosis/Neuromyelitis optica | 0 |
14 | Chronic inflammatory demyelinating polyneuropathy | 0 |
16 | Crow-Fukase syndrome | 0 |
28 | Systemic amyloidosis | 1 |
35 | Pemphigus | 0 |
46 | Malignant rheumatoid arthritis | 0 |
53 | Sjogren syndrome | 0 |
63 | Idiopathic thrombocytopenic purpura | 0 |
64 | Thrombotic thrombocytopenic purpura | 0 |
65 | Primary immunodeficiency | 0 |
70 | Spinal stenosis | 0 |
74 | Prolactin secreting pituitary adenoma | 0 |
75 | Cushing disease | 0 |
81 | Congenital adrenal hyperplasia | 0 |
83 | Addison disease | 0 |
84 | Sarcoidosis | 0 |
90 | Retinitis pigmentosa | 0 |
96 | Crohn disease | 0 |
97 | Ulcerative colitis | 0 |
162 | Pemphigoid | 0 |
222 | Primary nephrotic syndrome | 0 |
235 | Hypoparathyroidism | 0 |
283 | Acquired pure red cell aplasia | 0 |
296 | Biliary atresia | 0 |
299 | Cystic fibrosis | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01527032 (ClinicalTrials.gov) | September 2002 | 28/7/2011 | Risk-adapted Therapy for Primary Systemic (AL) Amyloidosis | Risk-adapted Therapy for AL Amyloidosis | Amyloidosis | Drug: melphalan, thalidomide and dexamethasone | FDA Office of Orphan Products Development | NULL | Completed | Phase 2 | NULL |